HBMHF.US HBM Holdings Limited

Healthcare Biotechnology USA Stocks
1.56 USD
Close of Nov 12, 2026
1.56 2.52
Market cap
USD 1.36B
P/E
13.0x
P/B
3.55x
ROE
62.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is HBMHF.US undervalued?

Graham number
Price1.56
Graham value1.09
Premium43.2%

HBMHF.US trades 43.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HBM Holdings Limited fundamental analysis

No fundamental analysis for HBM Holdings Limited yet.

HBM Holdings Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HBM Holdings Limited

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively …

Full company profile